Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 218

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 5
Chunk 218
---
 balance during the year ended December 31, 2024 was primarily a result of amounts recognized as revenue and the impact of foreign currency, partially offset by cash payments received in advance of satisfying performance obligations.  Revenue recognized during the years ended December 31, 2024 and 2023 that was included in the opening contract liability balance each year was approximately $1.3 billion.

71

NOTE 6.  SEGMENT INFORMATION 

The Company operates and reports its results in three separate business segments consisting of the Biotechnology, Life Sciences and Diagnostics segments.  Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes.  The identifiable assets by segment are those used in each segment’s operations.  Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.  The Company’s President and Chief Executive Officer is the chief operating decision maker (“CODM”).  The CODM uses segment sales and operating profit to allocate resources (including employees and financial or capital resources), to assess the performance of the segments and in the determination of the compensation for certain employees for each segment predominantly in the annual budget process.  The CODM reviews forecast-to-actual variances in segment sales and operating profit on a monthly basis when making decisions about allocating capital and personnel to the segments. The table below reconciles segment sales to segment operating profit with the expense categories presented reflecting the expenses that the Company has determined to be significant segment expenses.  Significant segment expenses are the expense category details regularly provided to the CODM to allocate resources to the segments and to evaluate segment performance.  Detailed segment data for the years ended December 31 is as follows ($ in millions):BiotechnologyLife SciencesDiagnosticsOther (a)Total CompanyYear Ended December 31, 2024Sales (GAAP)$6,759 $7,329 $9,787 $— $23,875 Less:Depreciation(151)(167)(394)(9)(721)Amortization of intangible assets(863)(576)(192)— (1,631)Impairments(b)— (222)(43)— (265)Other segment expenses(c)(4,060)(5,485)(6,533)(317)(16,395)Operating profit$1,685 $879 $2,625 $(326)$4,863 Year Ended December 31, 2023Sales (GAAP)$7,172 $7,141 $